Inventiva SACA

Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30 май 2024 02:30:00 Источник Nasdaq GlobeNewswire

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

30 май 2024 02:30:00 Источник Nasdaq GlobeNewswire

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

22 май 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

21 май 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

16 май 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

13 май 2024 02:30:00 Источник Nasdaq GlobeNewswire

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

03 апр 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the nomination of Andre Turenne as Director

28 мар 2024 03:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports its 2023 full-year results

27 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

22 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

18 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

13 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

07 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

15 фев 2024 16:35:00 Источник Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 янв 2024 16:15:00 Источник Nasdaq GlobeNewswire

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

10 янв 2024 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

20 дек 2023 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

04 дек 2023 16:05:00 Источник Nasdaq GlobeNewswire

Inventiva reports 2023 Third Quarter Financial Information¹

21 ноя 2023 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

06 ноя 2023 16:00:00 Источник Nasdaq GlobeNewswire